JPS6241511B2 - - Google Patents
Info
- Publication number
- JPS6241511B2 JPS6241511B2 JP54115376A JP11537679A JPS6241511B2 JP S6241511 B2 JPS6241511 B2 JP S6241511B2 JP 54115376 A JP54115376 A JP 54115376A JP 11537679 A JP11537679 A JP 11537679A JP S6241511 B2 JPS6241511 B2 JP S6241511B2
- Authority
- JP
- Japan
- Prior art keywords
- aromatic ring
- compound
- distilled
- add
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000007657 benzothiazepines Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- -1 S-(p-toluenesulfonylimino)thiochroman-4-one Chemical compound 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- USSBIWCJIPKRKJ-UHFFFAOYSA-N (nz)-4-methyl-n-(2-methyl-4-oxo-2,3-dihydrothiochromen-1-ylidene)benzenesulfonamide Chemical compound CC1CC(=O)C2=CC=CC=C2S1=NS(=O)(=O)C1=CC=C(C)C=C1 USSBIWCJIPKRKJ-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- CVQSWZMJOGOPAV-UHFFFAOYSA-N 2,3-dihydrothiochromen-4-one Chemical compound C1=CC=C2C(=O)CCSC2=C1 CVQSWZMJOGOPAV-UHFFFAOYSA-N 0.000 description 1
- BYWVVMGBFKFYMY-UHFFFAOYSA-N 6-methyl-2,3-dihydrothiochromen-4-one Chemical compound S1CCC(=O)C2=CC(C)=CC=C21 BYWVVMGBFKFYMY-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 1
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
Description
本発明は、次の一般式（）
〔式中、R1は水素、ハロゲン又は低級アルキル
を、R2、R3は同一又は異なつて水素又は低級ア
ルキルを、ＴSは
The present invention is based on the following general formula () [In the formula, R 1 is hydrogen, halogen or lower alkyl, R 2 and R 3 are the same or different and are hydrogen or lower alkyl, and T S is
【式】を表わ
す。〕で示されるベンゾチアゼピン系誘導体に関
する。
該物質は、種々の方法で製造することができる
が、たとえば次の一般式（）
〔式中R1、R2、R3、ＴSは前記と同じ。〕
で表わされる化合物をベンゼンあるいはアセトニ
トリルに溶かしてシリカゲルあるいはトリエチル
アミンと室温で数時間撹拌することにより製造す
ることができる。
あるいは次の一般式（）
〔式中R1、R2、R3、ＴSは前記と同じ。ｎは０あ
るいは１を表わす。〕で示される化合物を、ｎ＝
０の場合はメチルアルコール中酢酸触媒で冷却下
あるいは室温でクロラミン−Ｔと反応させること
により、一方ｎ＝１の場合はクロロホルムあるい
はアセトニトリル溶媒でトリエチルアミンと反応
させるかあるいはエタノール溶媒で加熱還流する
ことにより収率よく製造することが出来る。
次に実施例において詳述する方法によつて合成
された本発明化合物を下記に示す。Represents [formula]. ] The present invention relates to a benzothiazepine derivative represented by This substance can be produced by various methods, for example, the following general formula () [In the formula, R 1 , R 2 , R 3 , and T S are the same as above. ] It can be produced by dissolving the compound represented by the formula in benzene or acetonitrile and stirring it with silica gel or triethylamine at room temperature for several hours. Or the following general formula () [In the formula, R 1 , R 2 , R 3 , and T S are the same as above. n represents 0 or 1. ], n=
0 by reacting with chloramine-T in methyl alcohol with an acetic acid catalyst under cooling or at room temperature, while n = 1 by reacting with triethylamine in chloroform or acetonitrile solvent, or by heating to reflux in ethanol solvent. It can be produced with good yield. Next, compounds of the present invention synthesized by the method detailed in Examples are shown below.
【表】【table】
【表】
本発明の化合物（）は文献未載の新規物質で
あつて、自発運動抑制作用、鎭痛消炎作用、抗菌
作用を有する極めて有用な化合物である。
次に本発明の製造に係る実施例を挙げて本発明
をさらに詳細に説明する。
実施例 １
２−（ｐ−トルエンスルホニル）−２・３・４・
５−テトラヒドロ−１・２−ベンゾチアゼピン
−５−オン（化合物番号１）
Ｓ−（ｐ−トルエンスルホニルイミノ）チオク
ロマン−４−オン300mgをエタノール30mlに溶か
し加熱還流を５時間する。反応後、エタノールを
留去し、残渣をメタノールより再結晶し、化合物
(1)を197mg得る。
NMR（in CDCl3）、δ；2.30（3H、ｓ、
CH3）、3.27（2H、m.−COCH2−）、4.12（2H、
m.〓NCH2−）、6.94（2H、d.芳香環、Ｊ＝8.5
Hz．）、7.40（2H、d.芳香環Ｊ＝8.5Hz．）
7.15〜7.70（4H、m.芳香環）
元素分析値（％）
計算値 Ｃ 57.63 Ｈ 4.53 Ｎ 4.20
実測値 Ｃ 57.75 Ｈ 4.46 Ｎ 4.02
実施例 ２
２−（ｐ−トルエンスルホニル）−２・３・４・
５−テトラヒドロ−１・２−ベンゾチアゼピン
−５−オン（化合物番号１）
チオクロマン−４−オン2.6ｇをメタノール50
mlに溶かし氷冷撹拌下クロラミンＴのメタノール
溶液をゆつくり加える。その後酢酸２滴を加え室
温で１時間反応させる。反応終了後メタノールを
留去し、残渣にエーテルを加え不溶物を除き、エ
ーテル溶液をカラムクロマトで分離する。ベンゼ
ン−酢酸エチル溶出部より化合物(1)を得る。
NMR、元素分析値は実施例１と同じ。
実施例 ３
７−メチル−２−（ｐ−トルエンスルホニル）−
２・３・４・５−テトラヒドロ−１・２−ベン
ゾチアゼピン−５−オン（化合物番号２）
６−メチルチオクロマン−４−オン2.00mgをメ
タノール50mlに溶かしメタノールに溶かしたクロ
ラミンＴを加える。酢酸0.1mlを加え１時間室温
にて撹拌する。反応終了後メタノールを留去。残
渣をクロロホルムに溶かし、水洗、硫酸マグネシ
ウムにて乾燥、クロロホルムを留去、残渣にメタ
ノールを加え放置する。不溶物を取除き、カラム
クロマトにて分離精製する。クロロホルム溶出部
より化合物(2)を853mg得る。
NMR（CDCl3）、δ；2.30（6H、s.CH3）、3.20
（2H、m.−COCH2−）、4.05（2H、m.−NCH2
−）、6.95（2H、d.芳香環、Ｊ＝８Hz）、7.10
（2H、m.芳香環）、7.38（1H、m.芳香環）、7.39
（2H、d.芳香環、Ｊ＝８Hz）
元素分析値（％）
計算値 Ｃ 58.76 Ｈ 4.93 Ｎ 4.03
実測値 Ｃ 58.58 Ｈ 5.14 Ｎ 3.94
実施例 ４
７−クロロ−２−ｐ−トルエンスルホニル−
２・３・４・５−テトラヒドロ−１・２−ベン
ゾチアゼピン−５−オン（化合物番号３）
６−クロロ−Ｓ−（ｐ−トルエンスルホニルイ
ミノ）チオクロマン−４−オン800mgをクロロホ
ルム100mlに溶かし、トリエチルアミン0.1mlを加
え30分間室温にて撹拌する。反応終了後、塩酸で
酸性とし水洗、硫酸マグネシウムにて乾燥、クロ
ロホルムを留去し、エタノールより再結晶する。
733mgの化合物(3)を得る。
NMR（CDCl3）、δ；2.31（3H、s.CH3）、3.23
（2H、m.−COCH2−）、4.10（2H、m.−NCH2
−）、6.99（2H、d.芳香環 Ｊ＝８Hz）、7.20
（2H、s.芳香環）、7.39（2H、d.芳香環 Ｊ＝８
Hz）、7.55（1H、m.芳香環）
元素分析値（％）
計算値 Ｃ 52.24 Ｈ 3.84 Ｎ 3.81
実測値 Ｃ 52.12 Ｈ 3.87 Ｎ 3.44
実施例 ５
３−メチル−２−ｐ−トルエンスルホニル−
２・３・４・５−テトラヒドロ−１・２−ベン
ゾチアゼピン−５−オン（化合物番号４）
Ｎ−〔２−（１−オキソ−２−プテニイル）フエ
ニルチオ〕−ｐ−トルエンスルホンアミド0.5ｇを
30mlのアセトニトリルに溶かし、トリエチルアミ
ンを0.1ml加える。室温で一昼夜反応させ、その
後アセトニトリルを留去、残渣をクロロホルムに
溶かし、1N−塩酸で洗浄後水洗、硫酸マグネシ
ウムにて乾燥クロロホルム留去後、カラムクロマ
トにて分離精製し、151mgの化合物(4)を得る。
NMR（CDCl3）、δ；1.94（3H、d.CH3、Ｊ＝
６Hz）、2.21（3H、s.Ts−CH3）、2.64（1H、m.
−COCH2−）、3.50（1H、m.COCH2）、4.70
（1H、m.COCH3）、6.84（2H、d.芳香環 Ｊ＝８
Hz）、7.10−7.55（4H、m.芳香環）、7.32（2H、
d.芳香環 Ｊ＝８Hz）。
元素分析値（％）
計算値 Ｃ 58.76 Ｈ 4.93 Ｎ 4.03
実測値 Ｃ 58.61 Ｈ 4.93 Ｎ 4.15
実施例 ６
３−メチル−２−ｐ−トルエンスルホニル−
２・３・４・５−テトラヒドロ−１・２−ベン
ゾチアゼピン−５−オン（化合物番号４）
Ｓ−（ｐ−トルエンスルホニルイミノ）−２−メ
チル−チオクロマン−４−オン４ｇをアセトニト
リル200mlに溶かしトリエチルアミンを２ml加え
る。室温で３時間撹拌し、その後アセトニトリル
を留去し、クロロホルム200mlに溶かし、希塩酸
で洗浄後、水洗、硫酸マグネシウムで乾燥、その
後クロロホルムを留去し、カラムクロマトにて分
離精製し1.34ｇの化合物(4)を得る。NMR、元素
分析値は実施例５と同じ。
実施例 ７
３・７−ジメチル−２−ｐ−トルエンスルホニ
ル−２・３・４・５−テトラヒドロ−１・２−
ベンゾチアゼピン−５−オン（化合物番号５）
Ｓ−（ｐ−トルエンスルホニルイミノ）−２・６
−ジメチル−チオクロマン−４−オン5.3ｇを250
mlのアセトニトリルに溶かし２mlのトリエチルア
ミンを加える。室温で２時間撹拌後、アセトニト
リルを留去し、残渣をベンゼンに溶かし、水洗、
硫酸マグネシウムにて乾燥、ベンゼンを大部分留
去し、析出した結晶を取除き、残渣をカラムクロ
マトにて分離精製し化合物(5)を1.84ｇ得る。
NMR（CDCl3）、δ；1.44（3H、d.CH3、Ｊ＝
６Hz）、2.23（3H、s.CH3）、2.26（3H、s.
CH3）、2.64（1H、m.−COCH2−）、3.50（1H、
m.−COCH2−）、4.68（1H、m.〓CH−CH3）、
6.89（2H、d.Ts−Ｈ、Ｊ＝５Hz）、7.08（2H、m.
芳香環）、7.35（1H、m.芳香環）、7.36（2H、d.
Ts−Ｈ、Ｊ＝５Hz）
元素分析値（％）
計算値 Ｃ 59.81 Ｈ 5.31 Ｎ 3.88
実測値 Ｃ 59.83 Ｈ 5.38 Ｎ 4.04
実施例 ８
４−メチル−２−（ｐ−トルエンスルホニル）−
２・３・４・５−テトラヒドロ−１・２−ベン
ゾチアゼピン−５−オン（化合物番号６）
Ｎ−〔２−（１オキソ−２−プロペニル）フエニ
ルチオ〕−ｐ−トルエンスルホンアミド138mgをベ
ンゼン６mlに溶かし、冷却後シリカゲル300mgを
加え室温で２時間撹拌する。シリカゲルを過に
より取り除き、液を減圧留去し、メタノールか
ら再結晶して104mgの純粋な化合物(6)を得る。
NMR（CDCl3）、δ；1.15−1.26（m.3H）、
2.24（s.3H）、３・６−４・２（m.3H）、6.85−
7.7（m.8H）。
元素分析値（％）
計算値 Ｃ 58.76 Ｈ 4.93 Ｎ 4.03
実測値 Ｃ 58.67 Ｈ 4.87 Ｎ 4.06[Table] The compound () of the present invention is a new substance that has not been described in any literature, and is an extremely useful compound having locomotor activity suppressing activity, anti-inflammatory activity for pain relief, and antibacterial activity. Next, the present invention will be explained in more detail by giving examples related to the production of the present invention. Example 1 2-(p-toluenesulfonyl)-2.3.4.
5-Tetrahydro-1,2-benzothiazepin-5-one (Compound No. 1) 300 mg of S-(p-toluenesulfonylimino)thiochroman-4-one was dissolved in 30 ml of ethanol and heated under reflux for 5 hours. After the reaction, ethanol was distilled off, the residue was recrystallized from methanol, and the compound
Obtain 197 mg of (1). NMR (in CDCl 3 ), δ; 2.30 (3H, s,
CH 3 ), 3.27 (2H, m.−COCH 2 −), 4.12 (2H,
m.〓NCH 2 −), 6.94 (2H, d. aromatic ring, J=8.5
Hz. ), 7.40 (2H, d. aromatic ring J = 8.5Hz.) 7.15-7.70 (4H, m. aromatic ring) Elemental analysis value (%) Calculated value C 57.63 H 4.53 N 4.20 Actual value C 57.75 H 4.46 N 4.02 Implementation Example 2 2-(p-toluenesulfonyl)-2・3・4・
5-tetrahydro-1,2-benzothiazepin-5-one (compound number 1) 2.6 g of thiochroman-4-one was dissolved in methanol 50 g.
ml and slowly add a methanol solution of chloramine T while stirring on ice. Then, add 2 drops of acetic acid and allow to react at room temperature for 1 hour. After the reaction is complete, methanol is distilled off, ether is added to the residue to remove insoluble matter, and the ether solution is separated by column chromatography. Compound (1) is obtained from the benzene-ethyl acetate eluate. NMR and elemental analysis values are the same as in Example 1. Example 3 7-Methyl-2-(p-toluenesulfonyl)-
2,3,4,5-tetrahydro-1,2-benzothiazepin-5-one (compound number 2) Dissolve 2.00 mg of 6-methylthiochroman-4-one in 50 ml of methanol and add chloramine T dissolved in methanol. Add 0.1 ml of acetic acid and stir at room temperature for 1 hour. After the reaction is complete, methanol is distilled off. The residue was dissolved in chloroform, washed with water, dried over magnesium sulfate, chloroform was distilled off, methanol was added to the residue, and the mixture was allowed to stand. Insoluble materials are removed and separated and purified using column chromatography. 853 mg of compound (2) was obtained from the chloroform eluate. NMR (CDCl 3 ), δ; 2.30 (6H, s.CH 3 ), 3.20
(2H, m.−COCH 2 −), 4.05 (2H, m.−NCH 2
−), 6.95 (2H, d. aromatic ring, J=8Hz), 7.10
(2H, m. aromatic ring), 7.38 (1H, m. aromatic ring), 7.39
(2H, d. aromatic ring, J=8Hz) Elemental analysis value (%) Calculated value C 58.76 H 4.93 N 4.03 Actual value C 58.58 H 5.14 N 3.94 Example 4 7-chloro-2-p-toluenesulfonyl-
2,3,4,5-tetrahydro-1,2-benzothiazepin-5-one (compound number 3) Dissolve 800 mg of 6-chloro-S-(p-toluenesulfonylimino)thiochroman-4-one in 100 ml of chloroform. Add 0.1 ml of triethylamine and stir at room temperature for 30 minutes. After the reaction is completed, the mixture is acidified with hydrochloric acid, washed with water, dried over magnesium sulfate, chloroform is distilled off, and recrystallized from ethanol.
733 mg of compound (3) is obtained. NMR (CDCl 3 ), δ; 2.31 (3H, s.CH 3 ), 3.23
(2H, m.−COCH 2 −), 4.10 (2H, m.−NCH 2
−), 6.99 (2H, d. aromatic ring J=8Hz), 7.20
(2H, s. aromatic ring), 7.39 (2H, d. aromatic ring J=8
Hz), 7.55 (1H, m. aromatic ring) Elemental analysis value (%) Calculated value C 52.24 H 3.84 N 3.81 Actual value C 52.12 H 3.87 N 3.44 Example 5 3-Methyl-2-p-toluenesulfonyl-
2,3,4,5-tetrahydro-1,2-benzothiazepin-5-one (compound number 4) N-[2-(1-oxo-2-putenyl)phenylthio]-p-toluenesulfonamide 0.5 g of
Dissolve in 30ml of acetonitrile and add 0.1ml of triethylamine. The reaction was allowed to proceed at room temperature for one day, and then the acetonitrile was distilled off. The residue was dissolved in chloroform, washed with 1N hydrochloric acid, washed with water, dried over magnesium sulfate, and then separated and purified using column chromatography to obtain 151 mg of compound (4). get. NMR (CDCl 3 ), δ; 1.94 (3H, d.CH 3 , J=
6Hz), 2.21 (3H, s.Ts−CH 3 ), 2.64 (1H, m.
−COCH 2 −), 3.50 (1H, m.COCH 2 ), 4.70
(1H, m.COCH 3 ), 6.84 (2H, d. aromatic ring J=8
Hz), 7.10−7.55 (4H, m. aromatic ring), 7.32 (2H,
d. Aromatic ring J=8Hz). Elemental analysis value (%) Calculated value C 58.76 H 4.93 N 4.03 Actual value C 58.61 H 4.93 N 4.15 Example 6 3-Methyl-2-p-toluenesulfonyl-
2,3,4,5-tetrahydro-1,2-benzothiazepin-5-one (Compound No. 4) Add 4 g of S-(p-toluenesulfonylimino)-2-methyl-thiochroman-4-one to 200 ml of acetonitrile. Add 2 ml of dissolved triethylamine. Stirred at room temperature for 3 hours, then distilled off acetonitrile, dissolved in 200 ml of chloroform, washed with dilute hydrochloric acid, washed with water, dried over magnesium sulfate, then distilled off chloroform, separated and purified using column chromatography to obtain 1.34 g of the compound ( 4) Obtain. NMR and elemental analysis values are the same as in Example 5. Example 7 3,7-dimethyl-2-p-toluenesulfonyl-2,3,4,5-tetrahydro-1,2-
Benzothiazepin-5-one (compound number 5) S-(p-toluenesulfonylimino)-2.6
-dimethyl-thiochroman-4-one 5.3g 250g
Dissolve in ml of acetonitrile and add 2ml of triethylamine. After stirring at room temperature for 2 hours, acetonitrile was distilled off, the residue was dissolved in benzene, washed with water,
The mixture was dried over magnesium sulfate, most of the benzene was distilled off, the precipitated crystals were removed, and the residue was separated and purified using column chromatography to obtain 1.84 g of compound (5). NMR (CDCl 3 ), δ; 1.44 (3H, d.CH 3 , J=
6Hz), 2.23 (3H, s.CH 3 ), 2.26 (3H, s.
CH 3 ), 2.64 (1H, m.−COCH 2 −), 3.50 (1H,
m.−COCH 2 −), 4.68 (1H, m.〓CH−CH 3 ),
6.89 (2H, d.Ts-H, J=5Hz), 7.08 (2H, m.
aromatic ring), 7.35 (1H, m. aromatic ring), 7.36 (2H, d.
Ts-H, J=5Hz) Elemental analysis value (%) Calculated value C 59.81 H 5.31 N 3.88 Actual value C 59.83 H 5.38 N 4.04 Example 8 4-Methyl-2-(p-toluenesulfonyl)-
2,3,4,5-tetrahydro-1,2-benzothiazepin-5-one (compound number 6) 138 mg of N-[2-(1oxo-2-propenyl)phenylthio]-p-toluenesulfonamide was added to benzene. After cooling, add 300 mg of silica gel and stir at room temperature for 2 hours. The silica gel was removed by filtration, the liquid was distilled off under reduced pressure, and recrystallized from methanol to obtain 104 mg of pure compound (6). NMR ( CDCl3 ), δ; 1.15−1.26 (m.3H),
2.24 (s.3H), 3.6-4.2 (m.3H), 6.85-
7.7 (m.8H). Elemental analysis value (%) Calculated value C 58.76 H 4.93 N 4.03 Actual value C 58.67 H 4.87 N 4.06
Claims (1)
を、R2およびR3は同一又は異なつて水素又は低
級アルキル基を、ＴSは【式】を 表わす。〕で表わされるベンゾチアゼピン系誘導
体。 ２ 低級アルキルがメチルである特許請求の範囲
第１項記載の化合物。[Claims] First-order general formula () [In the formula, R 1 represents hydrogen, halogen or lower alkyl, R 2 and R 3 are the same or different and represent hydrogen or a lower alkyl group, and T S represents [Formula]]. ] A benzothiazepine derivative represented by 2. The compound according to claim 1, wherein lower alkyl is methyl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11537679A JPS5639081A (en) | 1979-09-08 | 1979-09-08 | Benzthiazepine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11537679A JPS5639081A (en) | 1979-09-08 | 1979-09-08 | Benzthiazepine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5639081A JPS5639081A (en) | 1981-04-14 |
| JPS6241511B2 true JPS6241511B2 (en) | 1987-09-03 |
Family
ID=14660987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11537679A Granted JPS5639081A (en) | 1979-09-08 | 1979-09-08 | Benzthiazepine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5639081A (en) |
-
1979
- 1979-09-08 JP JP11537679A patent/JPS5639081A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5639081A (en) | 1981-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0200638B1 (en) | Process for the preparation of (z)-1-phenyl-1-diethyl amino carbonyl 2-amino methyl cyclopropane hydrochloride | |
| EP0094102B1 (en) | 1-(1-cyclohexanyl-methyl) pyrrolidine derivatives, and process for their preparation | |
| EP0139584A2 (en) | Imidazoline derivatives, their preparation and therapeutical use | |
| ES2930284T3 (en) | Method for preparing a phenylalanine compound | |
| JPS6241511B2 (en) | ||
| JP3241889B2 (en) | Method for producing cyanoacylcyclopropane compound and 2-cyanoacyl-4-butanolide compound used therefor | |
| JPH032134B2 (en) | ||
| CN112479967B (en) | Biliverdin compound, and preparation method and application thereof | |
| JP2007506698A5 (en) | ||
| JPS6241510B2 (en) | ||
| BE884977A (en) | NOVEL N-PHENYL-BENZAMIDES USEFUL IN THE TREATMENT OF MAMMALIAN INFLAMMATION AND PAIN | |
| US5475118A (en) | 1-phenylpyrrolidone derivatives having optical activity, intermediate for the preparation thereof and processes for their preparation | |
| KR800001357B1 (en) | Process for the preparation of n-(2-substitute-ethyl-1)-3-benzoyl propion amide | |
| FR2511677A1 (en) | PROCESS FOR THE PREPARATION OF ESTERS OF ALCOXYVINCAMINIC ACIDS AND ALCOXYAPOVINCAMINE | |
| JPS61246176A (en) | Preparation of aminolactone | |
| JP2508152B2 (en) | 4-amino-5-fluoro-2-nitrophenoxyacetic acid ester | |
| JPH01100147A (en) | Optically active malonic acid ester derivative | |
| JP4937442B2 (en) | Process for producing 5-fluorooxindole | |
| CN117362192A (en) | PET radioactive tracer for imaging glycine transporter Glyt2 | |
| JP3256259B2 (en) | Method for producing sulfone derivative | |
| JPH0511115B2 (en) | ||
| JPS6321661B2 (en) | ||
| JPH0459315B2 (en) | ||
| JPH01163154A (en) | Production of tetrahydrophthalimide based compound, intermediate thereof and production of said intermediate | |
| JPS637188B2 (en) |